Join us for a dynamic and thought-provoking session with Dr. Niklas Mattsson-Carlgren of Lund University as he explores emerging perspectives on Alzheimer’s disease (AD) — including the concept of AD as an amyloid-driven tauopathy and what this means for the future of diagnosis and treatment.
Be part of the conversation during a live Q&A session chaired by Dr. Holly Brothers — your chance to engage directly with leaders in the field.
Reserve your spot now and stay informed on the evolving AD landscape.
Objectives:
- Explore the biomarker progression along the Alzheimer’s disease continuum, including biological diagnosis, Braak staging, and the correlation between pathology and clinical progression.
- Examine the relationship between amyloid and tau pathologies, and how Alzheimer’s disease may be considered an amyloid-driven tauopathy.
- Consider key evidence gaps in the understanding of amyloid-tau dynamics and future implications for biomarker development.
Holly M. Brothers, PhD
Associate Medical Director
Dr. Holly Brothers is a Medical Affairs professional with 8 years of experience in industry and nearly 20 years of experience in Alzheimer’s disease (AD). During her doctoral program at The Ohio State University and postdoc at the Sanders Brown Center on Aging ADRC, she studied the relationship between neuroinflammation, vascular pathology and AD hallmark pathologies in animal models. She has 28 peer-reviewed publications and 52 posters/oral presentations. She supported the U.S. launch the first amyloid-directed antibody for the treatment of early AD and currently supports the AD pipeline.
Niklas Mattsson-Carlgren, MD, PhD
Associate Professor of Clinical Neuroscience, board-certified in Neurology and Clinical Chemistry, Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University and Department of Neurology, Skåne Univers
Dr. Niklas Mattsson-Carlgren is a renowned Swedish physician and researcher from Lund University and co-lead of the BioFINDER studies. He specializes in neurodegenerative diseases, with a primary focus on AD, and has made significant contributions to the understanding of the early stages and progression of AD, particularly regarding biomarkers, brain imaging, and DMTs. He has published extensively and collaborated internationally to advance the fight against dementia-related illnesses, while also actively involved in mentoring the next generation of clinicians and scientists.